The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical landscape of precision oncology for rare cancers among diverse Asian populations: Insights from the MASTER KEY registry.
 
Chiharu Mizoguchi
No Relationships to Disclose
 
Hitomi Sumiyoshi Okuma
No Relationships to Disclose
 
Manabu Muto
Speakers' Bureau - Canon Medical System; Chugai Pharma; Daiichi Sankyo/Lilly; Illumina; Incyte Japan; Merck; MSD; Novartis; Olympus; Ono Pharmaceutical; Shionogi
Research Funding - Canon Medical System; Chugai Pharma; H.U. Group Holdings; Meiji Seika Kaisha; NTT; NTT Data; Taiho Pharmaceutical
 
Ichiro Kinoshita
Honoraria - AstraZeneca/Daiichi Sankyo; Bayer; Chugai Pharma; MSD; Takeda
 
Eishi Baba
Honoraria - Amgen; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Janssen; Lilly; Merck; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Daiichi Sankyo
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Masanobu Takahashi
Speakers' Bureau - Bristol-Myers Squibb Japan; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical
 
Masashi Ando
Speakers' Bureau - Chugai Pharma; Eisai; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hwoei Fen Soo Hoo
No Relationships to Disclose
 
Suhana Yusak
No Relationships to Disclose
 
Pei Jye Voon
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Janssen-Cilag (Inst); Johnson & Johnson (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); ROCHE (Inst); Viracta Therapeutics (Inst)
 
Rangasamy Ramachandran
No Relationships to Disclose
 
Muthukkumaran Thiagarajan
No Relationships to Disclose
 
Marcelo Severino Bulauitan Imasa
Consulting or Advisory Role - AstraZeneca; Pfizer
Speakers' Bureau - AstraZeneca; MSD; Pfizer; Roche; Sandoz
Research Funding - MSD; Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Rozita Abdul Malik
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Wonyoung Choi
Honoraria - Bayer; Daiichi Sankyo; MSD
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Eisai; TTY Biopharm
 
Tu Van Dao
Honoraria - AstraZeneca; Bayer; Eisai; Icon Cancer Care; Merck Serono; MSD; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - AstraZeneca; MSD; Novartis
Travel, Accommodations, Expenses - AstraZeneca
 
Tom Wei-Wu Chen
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Roche
Research Funding - Eisai; Epizyme
Travel, Accommodations, Expenses - Eisai; Roche
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Kenichi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Rakuten Medical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)